Revolution Medicines, Inc. (RVMD) Financials

NASDAQ:RVMD

Market Cap

3.39B

Total Revenue

35.38M

Gross Profit

35.38M

Operating Income

-258.28M

Net Income

-248.71M

Metric	2017	2018	2019	2020	2021	2022
revenue	--	20,165,000	50,041,000	42,983,000	29,390,000	35,380,000
costOfRevenue	--	--	--	--	--	--
grossProfit	--	20,165,000	50,041,000	42,983,000	29,390,000	35,380,000
researchAndDevelopmentExpenses	26,586,000	51,084,000	91,755,000	132,252,000	186,948,000	253,073,000
sellingAndMarketingExpenses	--	--	--	--	--	--
generalAndAdministrativeExpenses	4,543,000	9,410,000	12,406,000	21,428,000	30,450,000	40,586,000
sellingGeneralAndAdministrativeExpenses	4,543,000	9,410,000	12,406,000	21,428,000	30,450,000	40,586,000
operatingExpenses	31,129,000	60,494,000	104,161,000	153,680,000	217,398,000	293,659,000
operatingIncome	-31,129,000	-40,329,000	-54,120,000	-110,697,000	-188,008,000	-258,279,000
totalOtherIncomeExpensesNet	2,000	-2,121,000	2,083,000	2,167,000	917,000	9,154,000
ebitda	-29,836,000	-39,909,000	-48,589,000	-108,459,000	-187,079,000	-249,125,000
depreciationAndAmortization	1,188,000	1,764,000	5,531,000	2,238,000	929,000	9,154,000
interestIncome	105,000	777,000	2,189,000	2,238,000	929,000	9,154,000
interestExpense	103,000	116,000	106,000	71,000	12,000	-9,656,000
incomeBeforeTax	-31,127,000	-41,789,000	-52,037,000	-108,530,000	-187,091,000	-249,125,000
incomeTaxExpense	105,000	-1,344,000	-4,373,000	-371,000	-7,320,000	-420,000
netIncome	-31,127,000	-41,789,000	-47,664,000	-108,159,000	-179,771,000	-248,705,000
eps	-0.85	-1.15	-0.9	-1.97	-2.47	-3.08
epsdiluted	-0.85	-1.15	-0.9	-1.97	-2.47	-3.08
weightedAverageShsOut	36,473,121	36,473,121	52,902,309	54,874,119	72,806,079	80,626,525
weightedAverageShsOutDil	36,473,121	36,473,121	52,902,309	54,874,119	72,806,079	80,626,525
costAndExpenses	31,129,000	60,494,000	104,161,000	153,680,000	217,398,000	293,659,000
otherExpenses	--	-2,121,000	--	--	--	--

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

Redwood City, CA, US

Website

revmed.com

CEO

Dr. Mark A. Goldsmith Ph.D.

Employees

292

About the Company

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.